Skip to main content

Table 9 Robustness results for dolutegravir

From: A new validated stability-indicating RP-HPLC method for simultaneous quantification of dolutegravir and lamivudine in bulk and pharmaceutical dosage form

S. No. Parameter As such method Used %RSD for peak area (n = 6) Average retention time Plate count Tailing factor Resolution
1 Flow rate (± 0.1 mL/min) 1.0 mL/min 0.9 mL/min 0.8 6.687 50185 1.12 23.47
1.0 mL/min 0.9 6.367 55945 1.14 22.51
1.1 mL/min 1.2 6.354 53434 1.06 21.34
2 Column temperature (± 5 °C) 30 °C 25 °C 0.5 6.321 52290 1.11 22.49
30 °C 0.9 6.367 55945 1.16 22.51
35 °C 1.5 6.353 53457 1.07 22.37
3 Mobile phase composition Buffer:ACN:Methanol, 55:20:30% v/v 55:25:25 0.7 6.322 52235 1.08 22.48
55:20:30 0.9 6.367 55985 1.13 22.51
55:15:35 1.2 6.364 51769 1.04 22.58